Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program

Just – Evotec Biologics was awarded a new contract, valued at up to $49.9M, with the U.S. Department of Defense for the rapid development of monoclonal antibody-based drug product prototypes targeting plague.

Plague, an infectious disease caused by the bacterium Yersinia pestis (“Y. pestis”), is one of the designated targets of interest under the DOD’s Accelerated Antibodies Program. Just – Evotec is developing and manufacturing antibody prototypes targeting Y. Pestis at their J.POD Redmond, WA cGMP biomanufacturing facility.

The post Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program appeared first on Life Science Washington.

Click here to view original post